Evidence for a novel, effective approach to targeting carcinoma catabolism exploiting the first-in-class, anti-cancer mitochondrial drug, CPI-613.
Clinical targeting of the altered metabolism of tumor cells has long been considered an attractive hypothetical approach. However, this strategy has yet to perform well clinically. Metabolic redundancy is among the limitations on effectiveness of many approaches, engendering intrinsic single-agent r...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science (PLoS)
2022-01-01
|
| シリーズ: | PLoS ONE |
| オンライン･アクセス: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0269620&type=printable |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|